secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-08-26T23:59:59+00:00
Accession:  0001493152-24-033870
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte dosed first patient with LB-100 in new colorectal cancer trial with NKI and Roche support
--------------------------------------------------------------------------------

- Dosed first patient in clinical trial NCT06012734 for MSI Low metastatic colorectal cancer.
- Trial collaboration with Netherlands Cancer Institute (NKI); Roche supplies atezolizumab (Tecentriq).
- Second pharma-funded LB-100 immunotherapy trial; earlier GSK trial for clear cell ovarian cancer started 2024.
- Aims to bring immunotherapy to ~85% of colorectal cancer patients currently unresponsive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224033870/0001493152-24-033870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224033870/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer